LSE:HVO (hVIVO Plc)
About HVO
hVIVO plc is a United Kingdom-based specialist contract research organization (CRO). The Company is engaged in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. It provides end-to-end early clinical development services to its client base, which includes global biopharma companies. It offers a portfolio of approximately 10+ human challenge models to test a range of infectious and respiratory disease products, challenge agent manufacturing, specialist drug development, and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. It offers additional clinical field trial services, such as patient recruitment and clinical trial site services. It runs challenge studies in from its Whitechapel quarantine clinic, and its QMB clinic with its specialized on-site virology and immunology laboratory.
hVIVO Plc (LSE: HVO) Latest News

Investing Articles
Looking for UK shares to buy? This 19p small-cap down 5% today may be worth considering

Investing Articles
If he had $1m today, here’s how this Warren Buffett disciple would build wealth

Investing Articles
1 near-penny stock I’m buying for the last time at 19p

Investing Articles
1 penny stock mistake to avoid in 2025

Investing Articles
Would it be madness to buy this FTSE stock smashed by Donald Trump’s team picks?

Investing Articles
5 growth stocks under £1 Fools believe will soar

Growth Shares
Is this the best UK stock under £1 right now?

Investing Articles
Best AIM stocks to consider buying in October

Investing Articles
3 FTSE AIM 100 stocks I’d consider snapping up in October

Investing Articles
Here’s 1 UK stock that I think will soar in the next FTSE bull market

Investing Articles
Are penny stocks still worth buying in 2024?
